Prosecution Insights
Last updated: November 04, 2026
Application No. 19/444,587

MEASURING PULSE WAVE VELOCITY USING ULTRASOUND

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Jan 09, 2026
Priority
Aug 31, 2023 — provisional 63/535,822 +1 more
Examiner
DAVIS, AMELIE R
Art Unit
3793
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Bioprober Corporation
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
308 granted / 473 resolved
-4.9% vs TC avg
Strong +33% interview lift
Without
With
+33.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
40 currently pending
Career history
521
Total Applications
across all art units

Statute-Specific Performance

§101
9.2%
-30.8% vs TC avg
§103
36.0%
-4.0% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
38.7%
-1.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 473 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 - 9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is indefinite for the following reasons: There is there is insufficient antecedent basis for “the pressure wave motion” in the 3rd paragraph. It is unclear what is being referred to. It is unclear what is intended by “the pressure/pulse wave” in the 4th paragraph. It is unclear if the slash is intended to mean “and”, “or”, “and/or”, or something else. It is unclear how the method is a “method of measuring pulse wave velocity ("PWV")”, as the claimed method does not include any steps of measuring PWV. The preamble is thus disembodied from the method steps, which renders the scope unclear. Does the method measure PWV or not? Claim 2 is indefinite because there is unclear antecedent basis for “displacement information”. It is unclear if this is the displacement information in claim 1. Consequently, it is unclear if the ‘extracting’ is the ‘extraction’ referred to in claim 1, or if these are two different ‘extracting’ steps. Claim 3 is indefinite because it is unclear what is intended by “wall expansion signal/differential signal” and “pressure/pulse wave”. It is unclear if the slash is intended to mean “and”, “or”, “and/or”, or something else. Claims 4 and 5 are indefinite because it is unclear what is intended by “reference point/kernel”. It is unclear if the slash is intended to mean “and”, “or”, “and/or”, or something else. Claim 6 is indefinite because it is unclear what is intended by “resampling of slow-time signals/motion compensation”. It is unclear if the slash is intended to mean “and”, “or”, “and/or”, or something else. Claims 7 - 8 are indefinite by virtue of dependency. Claim 9 is indefinite because it is unclear what is meant by “the ultrasound pulses are at a frame rate of over 100 Hz”. Those of ordinary skill in the art would understand that a frame rate is the rate at which image frames are captured. However, the ultrasound pulses are the pulses that are transmitted into the tissue, rather than image frames. It is unclear how ultrasound pulses that are transmitted into the tissue may have a ”frame rate”, as they do not possess a frame. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 - 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 - 6 of U.S. Patent No. 12,551,196. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are directed to methods of measuring pulse wave velocity (“PWV”) in an arterial wall of a blood vessel utilizing ultrasound imaging (reference claim 1), comprising: placing of an ultrasound probe on an exterior tissue above the blood vessel (reference claim 1); transmitting ultrasound pulses from the ultrasound probe into the tissue, and receiving echo signals containing the pressure wave motion on the blood vessel wall (reference claim 1); tracking of longitudinal motion of the arterial wall as the pressure/pulse wave transits through the arterial wall (reference claim 1); and suppressing of longitudinal wall movement of the arterial wall on successive beamformed image frames of the arterial wall while extracting displacement information of the arterial wall (reference claim 1). Specifically: Claim 1 is suggested by reference claim 1. Claim 2 is suggested by reference claim 1. Claim 3 is suggested by reference claim 1. Claim 4 is suggested by reference claim 2. Claim 5 is suggested by reference claim 3. Claim 6 is suggested by reference claim 4. Claim 7 is suggested by reference claim 5. Claim 8 is suggested by reference claim 6. Claim 9 is suggested by reference claim 1. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 - 3 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rouet et al. (US 2022/0096048). Regarding claim 1, Rouet shows a method comprising: placing of an ultrasound probe on an exterior tissue above the blood vessel (non-invasive measure of blood vessel rigidity, abstract); transmitting ultrasound pulses from the ultrasound probe into the tissue, and receiving echo signals containing the pressure wave motion on the blood vessel wall (ultrasound data acquisitions, [0122] and steps 110, 120 in fig. 2); tracking of longitudinal motion of the arterial wall as the pressure/pulse wave transits through the arterial wall (motion of the blood vessel is determined, [0125] and step 130 in fig. 2; longitudinal tracking, [0140]); and suppressing of longitudinal wall movement of the arterial wall (correct for any longitudinal motion occurring during the cardiac cycle, [0140]) on successive beamformed image frames of the arterial wall (tracking algorithm is applied to the cineloop, [0137]) while extracting displacement information of the arterial wall (blood vessel wall displacement over time is determined, [0141]). The method is interpreted as being ‘of measuring pulse wave velocity ("PWV")’, lacking any positive recitation in the claim of a step of measuring the PWV. Regarding claim 2, Rouet discloses the claimed invention substantially as noted above. Rouet further shows suppressing of undulating motion of the arterial wall on successive beamformed image frames of the arterial wall while extracting displacement information of the arterial wall ([0140] - the axial tracking and/or longitudinal tracking and subsequent motion correction would provide at least partial suppression of motion that includes at least some ‘undulation’). Regarding claim 3, Rouet discloses the claimed invention substantially as noted above. Rouet further shows enhancing of a wall expansion signal/differential signal of the arterial wall due to the pressure/pulse wave ([0140] - the correction for longitudinal motion provides enhancement of any wall expansion signal by virtue of the correction). Regarding claim 8, Rouet discloses the claimed invention substantially as noted above. Rouet further shows the tracking is of multiphasic and bidirectional longitudinal displacements of anterior and posterior walls of the arterial wall during a cardiac cycle wall ([0140] - the longitudinal tracking would provide tracking that is of at least some ‘multiphasic and bidirectional longitudinal displacements’). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 4 is rejected under 35 U.S.C. 103 as being unpatentable over Rouet in view of Isla Garcia (US 2023/0277157 ). Regarding claim 4, Rouet discloses the claimed invention substantially as noted above. Rouet further shows the tracking comprises mapping pixel coordinates on the successive beamformed image frames of the arterial wall (“initial vessel boarder may be propagated automatically onto all the of the ultrasound image frames of the cineloop”, [0140]). Rouet is not specific to the pixel coordinates having a reference point/kernel centered thereon. Isla Garcia discloses generating microvessel images from image data acquired with an ultrasound system. Isla Garcia teaches pixel coordinates having a reference point/kernel centered thereon ([0026]; centroid of all of the tracking windows, [0057]; [0060]). It would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to have modified the invention of Rouet to include the pixel coordinates having a reference point/kernel centered thereon, as taught by Isla Garcia, in order to utilize parallelizable, convex constraints, as suggested by Isla Garcia ([0060]). Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Rouet in view of Alizad (US 2022/0087651). Regarding claim 9, Rouet discloses the claimed invention substantially as noted above. Rouet fails to show a frame rate of over 100 Hz. Alizad discloses generating microvessel images from image data acquired with an ultrasound system. Alizad teaches a frame rate of over 100 Hz (‘frame rate associated with an acquisition pulse repetition frequency (“PRF”) of at least 100 Hz’, [0100]). It would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to have modified the invention of Rouet to include a frame rate of over 100 Hz, as taught by Alizad, in order to achieve a high frame rate, as suggested by Alizad ([0100]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMELIE R DAVIS whose telephone number is (571)270-7240. The examiner can normally be reached Monday-Friday, 9:30 - 6:00 PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Pascal Bui-Pho can be reached at (571)272-2714. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMELIE R DAVIS/Primary Examiner, Art Unit 3798
Read full office action

Prosecution Timeline

Jan 09, 2026
Application Filed
Sep 14, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778442
Method And Apparatus For Moving A Reference Device
2y 7m to grant Granted Nov 03, 2026
Patent 12758353
A Fiducial Marker Set, A Method Of Determining A Position Of The Same And A Control System
2y 9m to grant Granted Oct 13, 2026
Patent 12758145
CONTACTLESS SLEEP DETECTION AND DISTURBANCE ATTRIBUTION FOR MULTIPLE USERS
2y 3m to grant Granted Oct 13, 2026
Patent 12751694
ULTRASONIC DIAGNOSTIC APPARATUS
2y 8m to grant Granted Oct 06, 2026
Patent 12733990
ELECTROMAGNETIC AND CAMERA-GUIDED NAVIGATION
2y 2m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
98%
With Interview (+33.2%)
3y 6m (~2y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 473 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month